IGF2 and chronic myelogenous leukemia, BCR-ABL1 positive: The association between increased IGF2 expression and poorer prognosis is well established, as shown by the elevated mortality in breast cancer [41], shorter recurrence times in oesophageal cancer [42], and faster progression in chronic myeloid leukemia [43].